What Relicof Treats: Main Uses and Benefits

Relicof is commonly used in acute and chronic conditions of the respiratory tract characterized by excessive secretions. It is indicated for easing symptoms in conditions such as acute bronchopulmonary diseases, chronic bronchitis, and bronchiectasis.

The primary therapeutic application is to manage symptoms of a productive but difficult cough, in situations involving thick or viscous mucus. This medication is considered relevant for easing symptoms that create noticeable physiological strain and is applied across therapeutic domains where additional symptomatic support is needed.

The medicine supports the patient during difficult episodes by easing distress and contributing to symptomatic relief during exacerbations and acute episodes. It may assist with maintaining functional stability in situations where thick secretions are present, which is relevant in contexts marked by increased discomfort or tension. For many patients, the key benefit is support for the difficulty of expectoration.

“The primary benefit is symptomatic support in situations where thick secretions interfere with routine breathing and comfort.”

It helps address symptom clusters that may become intense or disruptive, offering a supportive role that helps patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Difficult Expectoration

• Target Symptom: Productive cough hindered by thick phlegm.
• Therapeutic Focus: Targeting symptoms related to viscous secretions.
• Common Context: Acute respiratory infections or chronic disease flares.

• Patient Benefit: Contributes to patient comfort and assists with symptomatic relief.

Regulatory References

1. FDA Philippines Drug Information on Ambroxol

RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults (age 18 and older). The official prescribing information lists no absolute contraindications for its use.

Use Restrictions and Special Populations

Official regulatory documents identify several populations requiring restricted use or special monitoring:

• Gastrointestinal/Biliary Disorders: Patients with disorders that may interfere with bile acid circulation—such as severe pancreatic disorders or certain intestinal conditions (e.g., ileal resection)—should be monitored for new or worsening diarrhea. These conditions may also decrease the absorption of the medicine.
• Sodium Sensitivity: The medicine has a high sodium content. Patients sensitive to high sodium intake, such as those with heart failure, hypertension, or kidney problems (renal impairment), must be appropriately monitored for signs of fluid retention or high sodium levels.
• Pregnancy and Breastfeeding: Use during pregnancy is conditional as animal data suggest potential fetal harm. Breastfeeding is not recommended due to a lack of human data and the potential for serious adverse reactions in the infant.
• Use Not Established: Safety and effectiveness have not been established in pediatric patients (under 18 years). There are also no dedicated studies in patients with moderate-to-severe hepatic (liver) or renal impairment, placing them in the use-not-established category.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Relicof (Ambroxol hydrochloride) around specific pharmacodynamic conflicts, one documented pharmacokinetic effect, and clearance considerations in certain patient populations.

Interaction-Related Restrictions	Official Regulatory Documentation
Co-administration Restriction	The combination with cough suppressants (antitussives) is not recommended due to the risk of the suppressed cough reflex leading to excessive mucus accumulation and potential airway obstruction.
Exposure Modification	Administration alongside antibiotics (specifically Amoxicillin, Cefuroxime, and Erythromycin) is documented to result in an increase in the concentration of these antibiotics within the bronchopulmonary secretions.
General Interaction Scope	Official regulatory prescribing information states that no clinically relevant unfavourable interactions with other medications have been reported.

Population-Specific Clearance Note:

In patients with severe hepatic impairment or severe renal insufficiency, a reduction in the drug's total clearance is expected, which leads to an official note of increased systemic plasma exposure of the active substance or its metabolites.

---

The interaction profile is primarily defined by the not recommended pharmacodynamic combination with antitussives and the specific pharmacokinetic effect that enhances antibiotic tissue concentration. Beyond these documented instances, regulatory information does not report unfavorable drug-drug interactions or mandatory timing-based separation rules.

The mechanism of action for Relicof involves distinct pharmacodynamic pathways mediated by its components. The antitussive component acts centrally as an agonist of the Sigma-1 receptor in the brainstem's cough center. This agonistic interaction dampens the excitability of the neural network that controls the cough reflex, raising the threshold necessary for afferent sensory signals to initiate the response. This results in decreased excitability of the cough reflex arc.

Simultaneously, the antihistamine component functions as an antagonist of the Histamine H1 receptor in peripheral tissues. By blocking histamine from binding, the drug inhibits the molecular cascade that typically leads to increased vascular permeability and glandular output in the respiratory tract. This mechanism limits fluid leakage and inhibits histamine-mediated increases in glandular secretion.

Additionally, expectorant/mucolytic components alter the physical properties of respiratory secretions by reducing their viscosity and surface tension. This physicochemical change modulates the integrity of bronchial fluid to support removal from the airways, completing the system-level physiological modulation.

How to Use Relicof: Administration Guidelines

The use of Relicof is defined by specific administration instructions. These guidelines detail the required dosage, timing, and method of taking the medicine.

---

Administration Requirements

Instruction Domain	Requirement (Adult Dose)
Recommended Dosage	50 mg (10 mL) per dose.
Frequency and Timing	Twice daily, administered exactly every 12 hours.
Route of Administration	Take by mouth (orally) or via percutaneous endoscopic gastrostomy tubes (PEG-tubes).
Timing with Meals	Take at least 1 hour before or 2 hours after a meal.

---

Procedural Steps

To ensure proper use, the preparation and administration sequence should be followed as outlined in the prescribing information:

1. Preparation: Gently shake the Relicof bottle for a minimum of 30 seconds before measuring each dose.
2. Dosing: Measure the 50 mg (10 mL) dose using the appropriate tool.
3. Administration: Swallow the dose directly or administer it through a compatible PEG-tube (both silicone and polyurethane PEG tubes can be used).
4. Schedule Adherence: Repeat the entire process 12 hours after the first dose to maintain the required twice-daily frequency.

This structured protocol establishes the standardized conditions for administering the medicine, including the need to take it on an empty stomach and the necessary physical step of shaking the suspension prior to use.

Research Evidence / Overview of Studies for Relicof

---

Evidence for Acute and Chronic Conditions with Viscous Mucus

The active compound in Relicof was studied for conditions used in research exploring how symptoms change over time in patients with respiratory conditions, such as acute bronchitis and flare-ups of chronic bronchitis, that are marked by viscous mucus. This evidence primarily consists of short-term, randomized controlled trials (RCTs), many of which involve comparison with an inactive substance (placebo) or another treatment. The studies applied in research contexts involving fluctuating or unstable symptoms typically included both adults and children.

Research primarily focused on outcomes reflecting daily functioning or activity level. Studies monitored changes in patient-reported outcomes describing perceived discomfort, such as cough severity and the difficulty of expectoration. Studies report how symptoms evolved in the observed populations, noting changes measured during the study period in symptom scores and physical characteristics of sputum. Evidence contributes to understanding symptom patterns during these acute or episodic manifestations.

Supportive Evidence in Complicated Respiratory Contexts

Beyond routine conditions, the active compound in Relicof has been studied in research focusing on acute, complex clinical contexts. This includes studies involving hospitalized adults with lower respiratory infections or those undergoing surgery. These studies, which often use the compound alongside usual care, focused on outcomes related to systemic or functional imbalance.

Research exploring short-term symptom changes monitored outcomes describing episodic or acute changes, such as scores related to the patient’s perceived difficulty of clearing secretions and measurements of certain blood oxygen levels in studies focusing on more severe conditions. Findings from these research efforts contribute to understanding how patients reported their experience during studies conducted during periods of increased symptom activity.

---

⏱️ Long-Term Studies and Durability of Effect

The majority of the existing Randomized Controlled Trials for Relicof have follow-up durations were limited, typically running for a week or less, which is relevant in trials assessing short-term or episodic symptom patterns. Therefore, limited information for long-term outcomes is available when the compound is used continually. Research exploring long-term symptom changes was studied for some chronic conditions, and these studies report how symptoms evolved in the observed populations over defined time intervals that are longer than the typical acute treatment period.

What Researchers Still Seek to Understand

The evidence base for Relicof highlights what is known — and what is still uncertain — regarding the compound's use and includes several research limitation frames. Follow-up durations were limited in many pivotal short-term studies, meaning more long-term observational data would be needed to fully characterize extended effects. While many studies monitored patient-reported outcomes describing perceived discomfort, the sample sizes were modest in some specific subgroup analyses. The way researchers have chosen to measure outcomes linked to inflammatory or irritative states, such as cough severity and sputum properties, also shows recognized heterogeneity. These factors indicate that research is ongoing to address these limitations.

Key Studies & References

1. FDA Philippines Drug Information on Ambroxol (used for context on licensed indication and forms)

Common questions about Relicof (FAQ)

Q: Is Relicof known by any other names?

The core component of Relicof is Ambroxol hydrochloride, which is recognized by various compound names. This substance is chemically defined as the active metabolite of the older compound, Bromhexine. Official documents often identify the medicine by its active ingredient.

Q: How quickly should someone expect to notice the effects of Relicof?

Official product information states that the onset of action, which is when the medicine begins to work, typically occurs within 30 minutes of taking an oral dose. This time frame reflects observations made in research studies.

Q: What should be done if a dose of Relicof is missed?

Regulatory guidance describes taking a missed dose as soon as it is remembered. However, if the time is nearly approaching the next scheduled dose, the instruction is to skip the missed one entirely. Official documents advise against taking a double dose to compensate.

Q: Is Relicof safe for use during pregnancy or while breastfeeding?

Official prescribing information indicates that the medicine is not recommended for use during the first three months of pregnancy (the first trimester). Regulatory documents note that the medicine is excreted into breast milk. Due to these factors, use of the medicine during pregnancy and breastfeeding is generally not recommended in official documents.

Q: Is Relicof addictive or habit-forming?

Official regulatory references do not classify the active ingredient in Relicof as a controlled substance. Furthermore, official prescribing information does not mention a risk of addiction or habit formation when the medicine is used as described.

Q: What happens if Relicof is taken with alcohol?

Official safety information advises that consuming alcohol while using Relicof may increase the occurrence or severity of side effects such as dizziness and drowsiness. Therefore, official safety information advises that consumption of alcohol should be avoided or limited while taking this medicine.

Q: Are there any specific warnings about stopping Relicof suddenly?

Regulatory guidance describes that the medicine should not be stopped suddenly. Official information indicates that the medicine should only be discontinued after instruction from a healthcare provider.

Q: Is Relicof a controlled substance?

The active ingredient in Relicof is not listed as a controlled substance by regulatory agencies. This classification means the medicine is not subject to the same strict regulations concerning prescribing and dispensing as controlled substances.

Q: Does Relicof have a black box warning in the US?

Official U.S. regulatory documents do not list a Boxed Warning (often called a Black Box Warning) for Relicof. This type of warning is typically reserved for drugs that carry serious or life-threatening risks.

Q: Where can I find the official patient information leaflet for Relicof?

The Patient Information Leaflet (PIL) or Package Insert is published by the manufacturer and approved by regulatory bodies. This official document can typically be found on the website of the relevant government drug agency or on the public product information pages provided by the manufacturer.

Q: Can Relicof be considered a long-term treatment option?

Regulatory documents usually specify a limited duration of use for the medicine, often 7 to 10 days, when treating acute conditions. Official information indicates that use beyond this typical timeframe is a matter requiring further medical consultation.

Q: Are there any specific foods or drinks that should be avoided when using Relicof?

Official administration guidelines advise that Relicof must be taken on an empty stomach, meaning at least one hour before or two hours after eating a meal. No specific individual foods are restricted by official documentation beyond this necessary timing instruction.

Q: Can Relicof be used by people with high blood pressure?

Official safety information states that caution is necessary for individuals with pre-existing high blood pressure. This is because the decongestant component of the medicine has the potential to worsen this underlying condition.

Q: Are there any known interactions between Relicof and common over-the-counter pain relievers?

Official regulatory documents state that no clinically significant negative interactions have been reported between Relicof and other medications. This statement generally includes common over-the-counter pain relievers.

Q: Can older adults use Relicof safely?

Official safety information notes that older adults may be more susceptible to certain adverse effects. These effects primarily include issues related to the cardiovascular system or difficulty with urination.

Q: Can Relicof affect a person's ability to drive or operate machinery?

Official warnings state that Relicof can cause side effects like dizziness or drowsiness. The official warning advises that activities requiring full attention, such as driving a vehicle or operating machinery, should be avoided due to this risk.

Q: Is Relicof described as safe for people with kidney problems?

Official documents note that the medicine requires special consideration for individuals with impaired renal (kidney) function. The body's clearance of the drug or its breakdown products may be reduced in these patients, which is a factor requiring special consideration.

Q: What were the main outcomes of the clinical trials for Relicof?

Clinical trials primarily focused on patient-reported outcomes to describe the experience of individuals during the study period. Studies tracked changes in measures of perceived discomfort, such as scores related to cough severity and the difficulty of expectoration of mucus.

Q: Is Relicof appropriate for children?

Official prescribing information indicates that Relicof is considered appropriate for use in the pediatric population. However, regulatory documents include a note that children may exhibit increased sensitivity to certain central nervous system effects, such as nervousness and irritability.

Q: Does Relicof interact with herbal supplements?

According to the official interaction profile, there have been no reports of clinically significant negative interactions with other medications, which generally includes most herbal supplements.

Q: What should I tell my doctor about before starting Relicof?

Official safety information advises informing your healthcare provider about several key medical history points. This includes any use of Monoamine Oxidase Inhibitors (MAOIs) within the last two weeks, and pre-existing conditions such as heart disease, high blood pressure, or thyroid disorders.

Q: How is Relicof different from older medications in its class?

The medicine is defined by its active ingredient, which is classified as the active metabolite of the older drug Bromhexine. This designation indicates that the compound is the key chemical substance created when Bromhexine is processed by the body. This classification defines the unique action of Relicof as a mucolytic and secretolytic agent.

Q: What is the potential for Relicof to interact with birth control pills?

The official regulatory interaction profile states that there have been no reports of clinically significant negative interactions with other medications. This official statement includes common oral contraceptives (birth control pills).

Q: What conditions make a person ineligible to use Relicof?

The medicine is strictly contraindicated (not to be used) if an individual has taken a Monoamine Oxidase Inhibitor (MAOIs) in the previous 14 days. Official information also advises that caution is necessary when the medicine is used by patients with certain pre-existing conditions, such as heart disease, high blood pressure, or diabetes.

Q: How is Relicof typically packaged and supplied?

Relicof is supplied as a liquid dosage form, commonly an Oral Solution or Syrup. It is typically packaged in a glass bottle and includes a measuring device, such as a cup or dropper, to ensure the correct volume is administered.

Q: What are the official recommendations regarding Relicof and other prescriptions?

Regulatory documents advise against combining Relicof with other cough suppressants (antitussives) due to a potential risk of mucus buildup. In contrast, official information documents that the medicine, when used alongside certain antibiotics, is known to increase the antibiotic's concentration within respiratory secretions.

Q: Can Relicof be crushed or split?

Since Relicof is supplied as a liquid Oral Solution or Syrup, it is designed to be measured using the provided device and swallowed directly. The instructions for this dosage form do not include or permit the physical modification that would apply to a tablet or capsule, such as crushing or splitting.

Official Storage and Disposal Requirements

Official regulatory documents define strict conditions for storing and disposing of Relicof to ensure the medicine maintains its stability and safety. This information is based on labeled instructions from authoritative health agencies.

Requirement Area	Labeled Instructions (Standard)
Temperature & Protection	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Protect from moisture and excessive heat. Do not freeze.
Packaging	Keep the medicine in its original, tightly closed container and protect it from light. Stability is maintained until the expiration date if stored correctly.
Child Safety	Relicof must be kept strictly out of the sight and reach of children.
Disposal	Dispose of unused or expired medicine through an official drug take-back program. Avoid flushing the product down the toilet or placing it in household trash unless explicitly instructed otherwise by the manufacturer or a government agency.